SWM
EDIT icon

SHP Wealth Management’s Editas Medicine EDIT Stock Holding History

SHP Wealth Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$292 Hold
90
– – ﹤0.01% 1833
2026
Q1 		$222 Hold
90
– – ﹤0.01% 1723
2025
Q4 		$184 Buy
+90
New +$260 ﹤0.01% 1471

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SHP Wealth Management's EDIT Position: Q2 2026 in Review

SHP Wealth Management held its Editas Medicine (EDIT) position steady in Q2 2026 at 90 shares worth $292. The position accounts for ﹤0.01% of the portfolio, ranked #1833.

SHP Wealth Management first reported a position in EDIT in Q4 2025 and has held it in 3 quarters since. 215 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • SHP Wealth Management held 90 shares of Editas Medicine worth $292 as of Q2 2026.
  • SHP Wealth Management left its Editas Medicine share count unchanged in Q2 2026.
  • Editas Medicine made up ﹤0.01% of SHP Wealth Management's portfolio in Q2 2026, its #1833 holding.
  • SHP Wealth Management first reported a position in Editas Medicine in Q4 2025 and has held it in 3 quarters since.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on SHP Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.